Anti-tumor effect of proteasome inhibitor on canine urothelial carcinoma.

ABSTRACT: Canine urothelial carcinoma (cUC) is one of the most malignant tumors affecting dogs; however, its proliferative mechanism is yet to be fully elucidated. The ubiquitin-proteasome system (UPS) is an important metabolic pathway regulating protein degradation, and its dysfunction leads to apoptosis. We investigated the antitumor effect of the proteasome inhibitor bortezomib, which blocks the UPS. Bortezomib inhibited cell growth in cUC cell lines by inducing apoptosis in vitro. These findings suggest the potential of bortezomib as a novel therapeutic drug for dogs with cUC.

SUBMITTER: Kodera Y 

PROVIDER: S-EPMC11422692 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature